Does Humana Cover Vyvanse?

What Is Vyvanse and Why Does Insurance Tier Matter?

Vyvanse is a central nervous system stimulant containing lisdexamfetamine dimesylate. The FDA approved it first for ADHD in 2007 and later for moderate-to-severe binge eating disorder (BED) in adults in 2015, making it the only Schedule II stimulant with an FDA-approved BED indication [1]. Insurance tiers directly affect what you pay at the pharmacy. A Tier 1 drug might cost $5, $10; a Tier 4 brand-name drug can cost $150 or more per fill without meeting your deductible first.

How Formulary Tiers Work

Most Humana plans use a five-tier formulary structure. Tier 1 contains preferred generics. Tier 2 holds non-preferred generics. Tier 3 covers preferred brand-name drugs. Tier 4 covers non-preferred brands. Tier 5 includes specialty medications. Vyvanse, as a brand-name stimulant, historically sat at Tier 3 or Tier 4 on Humana commercial plans. With generic lisdexamfetamine now on the market, many plans have shifted the brand to a higher tier to encourage generic substitution.

Why Stimulants Often Require Extra Steps

Schedule II controlled substances face additional scrutiny from insurers beyond standard formulary placement. The Drug Enforcement Administration classifies lisdexamfetamine as Schedule II because of its high potential for dependence [2]. Insurers, including Humana, use this classification as one justification for requiring prior authorization, quantity limits, or step therapy before approving brand-name stimulants.

The 2023 Generic Launch Changes the Picture

Shire's Vyvanse patent protection ended, and generic lisdexamfetamine dimesylate became commercially available in the United States in August 2023. The FDA maintains a searchable database of approved generics at its Orange Book [3]. Most Humana plans updated their formularies within one to two plan years to prefer the generic. If your plan now lists lisdexamfetamine dimesylate (generic) at Tier 2 and brand Vyvanse at Tier 4, your prescriber can often write "dispense as written", but you will likely pay the higher brand cost without a separate exception approval.

Does Humana Cover Vyvanse on Commercial Plans?

Yes. Humana commercial group and individual market plans generally include Vyvanse or its generic equivalent on the formulary. Coverage specifics depend on whether your employer chose a plan with a closed or open formulary, and whether the plan year has been updated to reflect generic availability [4].

Checking Your Specific Plan

The single most reliable step is to log into Humana's member portal at humana.com and run a drug search under "Find a Drug." Enter "lisdexamfetamine" or "Vyvanse," your plan ID, and your pharmacy ZIP code. The tool returns the tier, any coverage restrictions, and the estimated copay. This search takes under two minutes and reflects your real-time formulary.

Prior Authorization Requirements

Humana's clinical criteria for Vyvanse prior authorization on commercial plans typically require [5]:

• A confirmed ADHD or BED diagnosis using DSM-5 criteria
• Documentation from a licensed prescriber (MD, DO, NP, or PA)
• For BED: confirmation that the patient is not underweight (BMI <18.5) and does not have a history of cardiovascular disease that contraindicates stimulant use
• For ADHD in adults: sometimes a trial of at least one generic amphetamine product first (step therapy)

The American Psychiatric Association's DSM-5 criteria define ADHD as a persistent pattern of inattention or hyperactivity-impulsivity that interferes with functioning in two or more settings [6].

Step Therapy: When Humana May Ask You to Try Something First

Some Humana commercial plans apply step therapy to Vyvanse, requiring a 30-day trial of mixed amphetamine salts (generic Adderall) before approving the branded or generic lisdexamfetamine. If that trial produces inadequate response or intolerable side effects, documented in the medical record, Humana will typically approve Vyvanse upon appeal or resubmission. Keep dated clinical notes describing the failed trial. These notes are the strongest evidence in an appeal.

Does Humana Medicare Cover Vyvanse?

Medicare coverage of Vyvanse is more complicated. Medicare Part D plans are prohibited from covering certain Schedule II stimulants used for weight loss, but ADHD and BED are distinct, medically accepted indications [7]. Humana's Medicare Part D prescription drug plans (PDP) and Medicare Advantage Prescription Drug (MAPD) plans may cover lisdexamfetamine when prescribed for ADHD or BED.

Part D Formulary Variability

Each Humana Medicare plan files its own formulary with the Centers for Medicare and Medicaid Services (CMS) annually. The CMS requires Part D sponsors to cover at least two drugs in each therapeutic class, but Schedule II stimulants are considered a "protected class" by some, though CMS does not classify them in the six protected drug classes that require all or substantially all drugs to be covered [8]. This means your specific Humana Medicare plan may or may not include Vyvanse.

The Coverage Gap (Donut Hole) and Its Phase-Out

Under the Inflation Reduction Act, the Medicare Part D coverage gap ("donut hole") was effectively eliminated starting January 1, 2025, capping annual out-of-pocket drug costs at $2,000 for Part D enrollees [9]. For Vyvanse patients on Medicare who previously faced a gap phase with full cost responsibility, 2025 plan year enrollment provides meaningful financial relief.

Checking Medicare Formulary Status

Visit the Medicare Plan Finder at medicare.gov/plan-compare or call 1-800-MEDICARE (1-800-633-4227). Enter your ZIP code, drug list, and preferred pharmacy. The tool compares every Humana Part D plan available in your area and shows the exact cost tier for lisdexamfetamine.

How Much Does Vyvanse Cost With Humana Insurance?

Cost depends on tier placement, deductible status, and whether you are filling brand or generic.

Brand Vyvanse Costs

Before meeting the deductible on a Humana commercial plan, brand Vyvanse's retail price can exceed $380 for a 30-day supply of 70 mg capsules [10]. After the deductible, the copay for a Tier 3 drug on a typical Humana commercial plan runs $45, $90. Tier 4 copays range from $80, $150+. These are estimates; your Summary of Benefits document lists exact copay tiers.

Generic Lisdexamfetamine Costs

Generic lisdexamfetamine dimesylate carries a substantially lower retail price, roughly $60, $180 per 30-day supply depending on the pharmacy and dosage strength, compared to the $380+ brand price [10]. On most Humana commercial formularies updated for 2024 and 2025, generic lisdexamfetamine sits at Tier 2, with copays of $15, $50.

Manufacturer Savings Programs

Takeda, the maker of brand Vyvanse, offers a savings card for commercially insured patients that may reduce the out-of-pocket cost to as low as $30 per fill. This program excludes Medicare, Medicaid, and other federal program beneficiaries, per federal anti-kickback statute restrictions [11]. Patients on government insurance should instead ask their pharmacist about state pharmaceutical assistance programs or Low Income Subsidy (LIS/Extra Help) status under Medicare Part D.

What to Do If Humana Denies Coverage

A denial is not a final answer. Federal law requires insurers to provide a clear reason for denial and a path to appeal.

Step 1: Understand the Denial Reason

Humana must send a written Explanation of Benefits (EOB) or denial notice specifying the reason, most often "prior authorization not obtained," "non-formulary drug," or "step therapy not satisfied." Read this document carefully before proceeding.

Step 2: File a Prior Authorization or Exception Request

Your prescriber submits a prior authorization (PA) request with clinical documentation. For ADHD, this typically includes office notes with DSM-5 symptom documentation, prior treatment history, and a rationale for why lisdexamfetamine is medically necessary over available alternatives. The Centers for Medicare and Medicaid Services requires Part D plans to respond to standard PA requests within 72 hours and expedited requests within 24 hours [12].

Step 3: Request a Formulary Exception

If Vyvanse is simply not on the formulary, a formulary exception request asks Humana to cover the drug anyway. The prescriber must document that all covered alternatives are contraindicated or have been tried and failed. The APA's practice guidelines for ADHD note that stimulant medications are first-line pharmacological treatment for ADHD across the lifespan [13], which supports medical necessity arguments.

Step 4: File an Internal Appeal, Then an External Review

If the PA or exception is denied, request an internal appeal. If that fails, you have the right to an independent external review under the Affordable Care Act for commercial plans. External reviewers are independent of Humana; their decision is binding on the insurer for ACA-compliant plans. The Department of Labor provides guidance on the external review process for employer-sponsored plans [14].

Step 5: State Insurance Commissioner Complaint

If the external review process stalls or if your plan is self-funded (which falls under ERISA rather than state law), contact your state insurance commissioner's office. For Medicare denials, file a complaint through medicare.gov or call the Medicare helpline.

Vyvanse for Binge Eating Disorder: Does Coverage Differ?

Coverage for the BED indication sometimes requires more documentation than the ADHD indication. Humana's clinical criteria for BED coverage typically specify that the patient has a documented diagnosis of moderate-to-severe BED per DSM-5 criteria, is 18 or older, and has been evaluated for cardiovascular risks before stimulant initiation [15].

Why Clinical Evidence Matters for the BED Indication

The key Phase 3 trials for lisdexamfetamine in BED, SPD489-343 and SPD489-344, enrolled a combined 724 adults and showed that lisdexamfetamine 50 mg and 70 mg reduced binge eating days per week by approximately 3.87 and 4.07 days respectively versus 2.51 days for placebo (P<0.001 for both doses) [16]. Sharing this published trial data with Humana's PA reviewers through your prescriber's office strengthens the medical necessity argument considerably.

BED Documentation Checklist

When submitting a PA for Vyvanse for BED, ask your prescriber to include:

• DSM-5 BED severity rating (moderate = 4 to 7 episodes/week, severe = 8+ episodes/week)
• Documented psychological or behavioral therapy attempted, if applicable
• Cardiovascular risk screening results (blood pressure, heart rate, ECG if indicated)
• Body weight confirming the patient is not underweight (BMI <18.5 is often listed as a contraindication in PA criteria)

Vyvanse Dosing Reference: What Humana's PA Reviewers See

Humana's clinical pharmacists review PA requests against FDA-approved dosing ranges. Prescriptions outside those ranges may trigger automatic denial.

FDA-Approved Dosing for ADHD

For ADHD in children ages 6 to 12, the FDA-approved starting dose is 20 to 30 mg once daily, titrated in increments of 10 to 20 mg at weekly intervals, to a maximum of 70 mg/day [1]. Adolescents (13 to 17) and adults follow the same titration range. Doses above 70 mg/day are not FDA-approved and will almost certainly be denied by Humana without extraordinary clinical justification.

FDA-Approved Dosing for BED

The FDA-approved dose range for BED is 50 to 70 mg once daily, with titration starting at 30 mg/day for the first week [1]. A prescription for 30 mg/day as a maintenance dose for BED falls outside the labeled maintenance range (50 to 70 mg) and may require additional documentation.

Alternatives Humana May Cover at Lower Cost

If Vyvanse coverage is denied or the cost remains prohibitive, several alternatives may sit at a lower tier on your Humana plan.

Generic Amphetamine Salts (Mixed Amphetamine Salts XR)

Generic mixed amphetamine salts extended-release (the generic form of Adderall XR) is available and sits at Tier 1 or Tier 2 on most Humana formularies. The FDA database lists multiple approved manufacturers [3]. Clinically, amphetamine salts and lisdexamfetamine share a similar mechanism; lisdexamfetamine is a prodrug that is converted to d-amphetamine after absorption, which some patients tolerate differently [17].

Methylphenidate Products

Generic methylphenidate immediate-release and extended-release formulations (generic Ritalin, generic Concerta) are Tier 1 or Tier 2 on nearly all Humana commercial and Medicare plans. A 2018 Cochrane review of 133 randomized controlled trials (N=10,068 children) found methylphenidate moderately improves teacher-rated ADHD symptoms versus placebo [18].

Non-Stimulant Options

Atomoxetine (generic Strattera) and viloxazine (Qelbree) are FDA-approved non-stimulant ADHD medications. Atomoxetine generic is Tier 1 on most plans. Viloxazine (Qelbree) is a newer brand-only option that may require its own PA. These are not Schedule II substances, which simplifies the prior authorization pathway.

Practical Steps Before Your Next Pharmacy Visit

Getting Vyvanse covered by Humana takes coordination between you, your prescriber, and the pharmacy. The sequence below reduces the chance of a surprise denial at the pharmacy counter.

1. Log into humana.com and confirm lisdexamfetamine (brand or generic) is on your plan's formulary before the appointment.
2. Ask your prescriber to submit a PA request at the time of writing the prescription, not after the pharmacy rejects it.
3. Request 90-day fills once the PA is approved. Many Humana commercial plans offer lower per-unit cost for 90-day mail-order fills through Humana Pharmacy.
4. If your plan prefers the generic, ask your prescriber whether generic lisdexamfetamine dimesylate is clinically acceptable. For most patients, it is bioequivalent to brand Vyvanse.
5. Apply for the Takeda savings card (if commercially insured) or the Takeda patient assistance program (if uninsured or underinsured) at the time of the first fill.